SLC5A2 and heart failure: Clinical trials from many countries, including the EASEL Population-Based Cohort Study [14], the EMPA-REG OUTCOME trial [15] and the CVD-REAL 2 study [16], have proven that SGLT2 inhibitors reduce the risk of non-fatal myocardial infarction, non-fatal stroke, and all-cause death, as well as the risk of hospitalization and death associated with heart failure.